0000000000505508

AUTHOR

Manfred Kaufmann

showing 6 related works from this author

Comparison of Prognostic Signatures in Node-Negative Tamoxifen-Treated Breast Cancer Patients.

2009

Abstract Background: A number of molecular signatures have been published to aid breast cancer prognosis and therapy response prediction. A 76-gene signature has been developed in a node-negative patient cohort that did not receive systemic therapy.1 Another prognostic 97-gene signature measures predominantly proliferation-associated genes.2 Finally, a 21-gene signature has been developed for node-negative and estrogen receptor–positive breast cancer patients treated with tamoxifen in the adjuvant setting.3 Here we compare the prognostic performance of all three published algorithms in a cohort of 189 node-negative breast cancer patients treated with tamoxifen.Materials and Methods: Fresh-f…

Subset AnalysisOncologyCancer Researchmedicine.medical_specialtyProportional hazards modelbusiness.industryCancermedicine.diseaseBioinformaticsSubclassNode negativeBreast cancerOncologyInternal medicineCohortmedicinebusinessTamoxifenmedicine.drugCancer Research
researchProduct

Anti-fetal immune response mechanisms may be involved in the pathogenesis of placental abruption

2003

Placental abruption is an unpredictable severe complication in pregnancy. In order to investigate the possibility that the activation of the fetal nonadaptive immune system may be involved in the pathogenesis of this disease, IL-6 release from cord blood monocytes was examined by intracellular cytokine staining and flow cytometric analysis. Our results demonstrate that preterm placental abruption (n = 15) in contrast to uncontrollable preterm labor (n = 33) is associated with significantly (P < 0.001) increased release of IL-6 from the fetal monocytes. The same holds true for rhesus disease (n = 9, P < 0.001) that is characterized by a maternal production of antibodies against the rhesus-D …

Time FactorsImmunologyAntibodiesMonocytesPreeclampsiaPathogenesisFetusObstetric Labor PrematureImmune systemHLA AntigensPregnancyHumansImmunology and AllergyMedicineAbruptio PlacentaeFetusPregnancybiologyPlacental abruptionbusiness.industryImmunityFetal Bloodmedicine.diseaseFetal circulationImmunologybiology.proteinFemaleAntibodybusinessClinical Immunology
researchProduct

Spontaneous labour at term is associated with fetal monocyte activation.

1999

SUMMARYThe aetiology of both term and preterm labour remains incompletely understood. Maternal infectious diseases as well as intra-uterine infections were shown to be a well established cause of uncontrollable preterm delivery, indicating that inflammatory reactions, regulated by maternal immunecompetent cells, are implicated in labour-promoting mechanisms. To investigate the possibility that the activation of the fetal immune system may be involved in labour induction, we examined cytokine production patterns of different cord blood cell populations obtained from neonates after spontaneous onset of normal term labour and vaginal delivery (n = 25), vaginal delivery but induced term labour …

medicine.medical_treatmentT cellImmunologyInflammationGestational AgeBetamethasoneMonocytesMagnesium SulfateImmune systemFetusObstetric Labor PrematurePregnancymedicineImmunology and AllergyHumansLabor InducedLungreproductive and urinary physiologyFenoterolFetusLabor Obstetricbusiness.industryVaginal deliveryCesarean SectionInterleukin-6MonocyteInfant NewbornDelivery ObstetricFetal Bloodmedicine.anatomical_structureCytokineTocolytic AgentsCord bloodImmunologyFemaleOriginal Articlemedicine.symptombusinessClinical and experimental immunology
researchProduct

Is first-line single-agent mitoxantrone in the treatment of high-risk metastatic breast cancer patients as effective as combination chemotherapy? No …

2002

BACKGROUND: To determine whether patients with high-risk metastatic breast cancer draw benefit from combination chemotherapy as first-line treatment. PATIENTS AND METHODS: A total of 260 women with measurable metastatic breast cancer fulfilling high-risk criteria, previously untreated with chemotherapy for their metastatic disease, were randomized to receive either mitoxantrone 12 mg/m(2) or the combination of fluorouracil 500 mg/m(2), epirubicin 50 mg/m(2) and cyclophosphamide 500 mg/m(2) (FEC) every 3 weeks. Treatment was continued until complete remission plus two cycles, or until disease progression. In the case of partial remission or stable disease, treatment was stopped after 12 cycl…

OncologyAdultmedicine.medical_specialtyLung NeoplasmsCyclophosphamidemedicine.medical_treatmentBone NeoplasmsBreast NeoplasmsRisk AssessmentSensitivity and SpecificityDisease-Free SurvivalStatistics NonparametricInternal medicineGermanyAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansCyclophosphamideAgedEpirubicinNeoplasm StagingProbabilityProportional Hazards ModelsChemotherapyMitoxantronePerformance statusbusiness.industryBiopsy NeedleLiver NeoplasmsCombination chemotherapyHematologyMiddle Agedmedicine.diseaseMetastatic breast cancerSurvival AnalysisSurgeryLogistic ModelsTreatment OutcomeOncologyQuality of LifeVindesineFemaleFluorouracilMitoxantronebusinessmedicine.drugEpirubicinAnnals of oncology : official journal of the European Society for Medical Oncology
researchProduct

O6-methylguanine-DNA methyltransferase activity in breast and brain tumors.

1995

The DNA repair protein O6-methylguanine-DNA methyltransferase (MGMT) is a main determinant of resistance of tumor cells to the cytostatic activity of chemotherapeutic alkylating agents (methylating and chloroethylating nitrosoureas) and is effective in protecting normal cells against genotoxic and carcinogenic effects resulting from DNA alkylation. Therefore, the level of expression of MGMT is significant for the response of both the tumor and the non-target tissue following application of nitrosoureas in tumor therapy. To determine the expression of MGMT in tumor tissue, we have assayed MGMT activity in 68 breast carcinomas and 38 brain tumors. There was a wide variation of MGMT expression…

AdultMaleCancer ResearchPathologymedicine.medical_specialtyMethyltransferaseDNA RepairMammary glandBlotting WesternBreast NeoplasmsBiologyAstrocytomaO(6)-Methylguanine-DNA MethyltransferaseGliomaDNA Repair ProteinmedicineCarcinomaHumansneoplasmsCarcinogenAgedEpitheliomaL-Lactate DehydrogenaseBrain NeoplasmsAstrocytomaMethyltransferasesMiddle Agedmedicine.diseasedigestive system diseasesmedicine.anatomical_structureOncologyCancer researchFemaleGlioblastomaHeLa CellsInternational journal of cancer
researchProduct

Preeclampsia, a pregnancy-specific disease, is associated with fetal monocyte activation.

2001

The maternal syndrome of preeclampsia is an exclusively pregnancy-related illness involving multiple organs and severe forms may be complicated by HELLP (hemolysis, elevated liver enzymes, low platelets) syndrome. Recently, it has been proposed that both normal pregnancy and preeclampsia are associated with a systemic activation of the nonspecific maternal immune system and that, in particular, monocytes have a central role in the adjustment of maternal immune functions in pregnancy. Here we have investigated the role of the fetal nonadaptive immune system in normal term delivery, uncontrollable preterm labor, and preeclampsia. We demonstrate that spontaneous delivery at term as well as pre…

medicine.medical_specialtyHELLP SyndromeHELLP syndromeImmunologyLipopolysaccharide ReceptorsInflammationBiologyMonocytesPreeclampsiaImmune systemFetusPre-EclampsiaPregnancyInternal medicinemedicineImmunology and AllergyHumansreproductive and urinary physiologyFetusPregnancyInnate immune systemInterleukin-6MonocyteHistocompatibility Antigens Class IHistocompatibility Antigens Class IImedicine.diseaseFetal BloodEndocrinologymedicine.anatomical_structureembryonic structuresImmunologyFemalemedicine.symptomClinical immunology (Orlando, Fla.)
researchProduct